Pulmonx sees FY25 revenue $96M-$98M, consensus $97.72M

The company said, “Pulmonx (LUNG) expects revenue for the full year 2025 to be in the range of $96 million to $98 million, representing growth of 15% to 17% compared to 2024, or 16% to 18% on a constant currency basis, as our guidance assumes a negative impact from foreign exchange on reported revenue growth of approximately 100 basis points. The Company expects gross margin for the full year 2025 to be approximately 74%. Pulmonx expects total operating expenses for the full year 2025 to fall within the range of $133 million to $135 million, inclusive of approximately $22 million of non-cash stock-based compensation.”